<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26751765</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.</ArticleTitle><Pagination><StartPage>916</StartPage><EndPage>921</EndPage><MedlinePgn>916-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1118595</ELocationID><Abstract><AbstractText Label="BACKGROUND">A primary goal of this study was to establish the serological mechanistic correlate of protection (mCoP) for an inactivated Enterovirus 71 (EV71) vaccine.</AbstractText><AbstractText Label="METHODS">We used the Prentice criterion framework and scaled logit model to explore the relationship between the neutralizing antibody (NTAb) and EV71-associated disease, and to build a protection curve for estimating the efficacy of EV71 vaccine. Data of NTAb at day 56 post-vaccination and the occurrence of EV71-associated disease during a 12-month follow-up period were collected from a phase 3 efficacy trial of EV71 vaccine in this study.</AbstractText><AbstractText Label="RESULTS">NTAb at day 56 post-vaccination in participants met the Prentice criterion framework. According to the protection curve, the antibody levels of 14.7, 27.8, 55.7, 129.0 and 459.4 (U/mL) were associated with 50%, 60%, 70%, 80% and 90% clinical protection rate, respectively. Vaccine efficacy predicted by the model was 81.5%, which was very similar to the actual vaccine efficacy of 80.4% (95% CI, 58.2, 90.8) observed in the phase 3 trial.</AbstractText><AbstractText Label="CONCLUSIONS">NTAb titers post-vaccination can be validated as mCoP for evaluating the efficacy of an inactivated enterovirus 71 vaccine, with a titers of 14.7 (U/ml) as a surrogate associated with the protection of 50% against EV71-associated disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>a Department of Epidemiology and Biostatistics , School of Public Health, Nanjing Medical University , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>b Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c College of Pharmacy, Third Military Medical University &amp; National Engineering Research Center for Immunological Products , Chongqing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuefeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>b Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fangyue</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>b Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>d School of Public Health, Southeast University , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xuejun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>a Department of Epidemiology and Biostatistics , School of Public Health, Nanjing Medical University , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Zhengkai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>d School of Public Health, Southeast University , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fengcai</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>a Department of Epidemiology and Biostatistics , School of Public Health, Nanjing Medical University , Nanjing , China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71 vaccine, Prentice criterion</Keyword><Keyword MajorTopicYN="N">correlate of protection</Keyword><Keyword MajorTopicYN="N">surrogate endpoints</Keyword><Keyword MajorTopicYN="N">the scaled logit model</Keyword><Keyword MajorTopicYN="N">vaccine efficacy trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26751765</ArticleId><ArticleId IdType="pmc">PMC4962943</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1118595</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kung YA, Hung CT, Liu YC, Shih SR. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 2014; 14:1455-64; PMID:24989170; http://dx.doi.org/10.1517/14712598.2014.935330</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2014.935330</ArticleId><ArticleId IdType="pubmed">24989170</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. Enterovirus vaccines for an emerging cause of brain-stem encephalitis. N Engl J Med 2014; 370:792-4; PMID:24571750; http://dx.doi.org/10.1056/NEJMp1400601</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1400601</ArticleId><ArticleId IdType="pubmed">24571750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097-105; PMID:20965438; http://dx.doi.org/10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-90; PMID:20961813; http://dx.doi.org/10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J 2013; 6:19780; PMID:24119538</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis 2015; 60:797-803; PMID:25352588; http://dx.doi.org/10.1093/cid/ciu852</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y,et&#xa0;al. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis 2014; 14:308-18; PMID:24485991; http://dx.doi.org/10.1016/S1473-3099(13)70342-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Lindsay K, Perera D, Chan HM, Chan KP, Cardosa MJ. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia Singapore,and Western Australia. J Virol 2001; 75:7732-8; PMID:11462047; http://dx.doi.org/10.1128/JVI.75.16.7732-7738.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7732-7738.2001</ArticleId><ArticleId IdType="pmc">PMC115010</ArticleId><ArticleId IdType="pubmed">11462047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010; 9:149-56; PMID:20109026; http://dx.doi.org/10.1586/erv.09.152</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH,et&#xa0;al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024-32; PMID:23726161; http://dx.doi.org/10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et&#xa0;al.. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370:829-37; PMID:24571755; http://dx.doi.org/10.1056/NEJMoa1303224</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et&#xa0;al.. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370:818-28; PMID:24571754; http://dx.doi.org/10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40; PMID:2727467; http://dx.doi.org/10.1002/sim.4780080407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780080407</ArticleId><ArticleId IdType="pubmed">2727467</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine. J Infect Dis 2007; 196:1304-12; PMID:17922394; http://dx.doi.org/10.1086/522428</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/522428</ArticleId><ArticleId IdType="pubmed">17922394</ArticleId></ArticleIdList></Reference><Reference><Citation>Golber PB, Qin L, Self SG. Evaluating a surrogate endpoint at three levels, with application to vaccine. Stat Med 2008; 27:4758-78; PMID:17979212; http://dx.doi.org/10.1002/sim.3122</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3122</ArticleId><ArticleId IdType="pmc">PMC2646675</ArticleId><ArticleId IdType="pubmed">17979212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohberger RC, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine 2008; 26:3516-21; PMID:18495303; http://dx.doi.org/10.1016/j.vaccine.2008.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.04.016</ArticleId><ArticleId IdType="pubmed">18495303</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA, Gilbert PB. Nomenclature for Immune Correlates of Protection After Vaccination. Clinical Infectious Disease 2012; 54:1615-7; http://dx.doi.org/10.1093/cid/cis238</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis238</ArticleId><ArticleId IdType="pmc">PMC3348952</ArticleId><ArticleId IdType="pubmed">22437237</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunning AJ. A model for immunological correlates of protection. Stat Med 2006; 25:1485-97; PMID:16158409; http://dx.doi.org/10.1002/sim.2282</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2282</ArticleId><ArticleId IdType="pubmed">16158409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff JC, Wittes J. Correlates, surrogates, and vaccines. J Infect Dis 2007; 196:1279-81; PMID:17922389; http://dx.doi.org/10.1086/522432</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/522432</ArticleId><ArticleId IdType="pubmed">17922389</ArticleId></ArticleIdList></Reference><Reference><Citation>Djomo PN, Thomas SL, Fine PEM. 
Correlates of vaccine-induced protection: methods and implications. World Health Organization
2013:1-49. http://www.who.int/vaccines-documents/</Citation></Reference><Reference><Citation>Nauta J. Statistics in clinical vaccine trials Vol. 8, Correlates of Protection. Heidelberg (Berlin: ): Springer; 2011. 107p.</Citation></Reference><Reference><Citation>Gilbert PB, Gabriel EE, Miao XP, Li XM, Su SC, Parrino J, Chan IS. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 2014; 210:1573-81; PMID:24823623; http://dx.doi.org/10.1093/infdis/jiu279</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu279</ArticleId><ArticleId IdType="pmc">PMC4215071</ArticleId><ArticleId IdType="pubmed">24823623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20:895-904; PMID:11738755; http://dx.doi.org/10.1016/S0264-410X(01)00385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007; 9:1299-306; PMID:17890123; http://dx.doi.org/10.1016/j.micinf.2007.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, Huang YC, Shih SR, Chiou ST, Chen PY, et&#xa0;al.. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002; 109:e88; PMID:12042582; http://dx.doi.org/10.1542/peds.109.6.e88</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.109.6.e88</ArticleId><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC. Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert Rev Anti Infect Ther 2014; 12:447-56; PMID:24579906; http://dx.doi.org/10.1586/14787210.2014.895666</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2014.895666</ArticleId><ArticleId IdType="pubmed">24579906</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox RJ. Correlates of protection to influenza virus, where do we go from here?. Hum Vaccin Immunother 2013; 9:405-8; PMID:23291930; http://dx.doi.org/10.4161/hv.22908</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.22908</ArticleId><ArticleId IdType="pmc">PMC3859764</ArticleId><ArticleId IdType="pubmed">23291930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Meng FY, Mao Q, Li JX, Wang H, Liang ZL, Zhang YT, Gao F, Chen QH, Hu Y, et&#xa0;al.. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother 2014; 10:1366-72; PMID:24633366; http://dx.doi.org/10.4161/hv.28397</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081-5; PMID:21983214; http://dx.doi.org/10.1097/INF.0b013e318236-7662</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e318236-7662</ArticleId><ArticleId IdType="pubmed">21983214</ArticleId></ArticleIdList></Reference><Reference><Citation>Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the protective concentration of anti-pneumococcal capsular polysccharide antibodies. Vaccine 2007; 25:3816-26; PMID:17368878; http://dx.doi.org/10.1016/j.vaccine.2007.01.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.01.119</ArticleId><ArticleId IdType="pubmed">17368878</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et&#xa0;al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29:9668-74; PMID:22015395; http://dx.doi.org/10.1016/j.vaccine.2011.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization 
Manual for the virological investigation of poliomyelitis World Health Organization
1997. 
http://WHO/EPI/CD5/POLIO/90.1.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>